Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis

10/08/2021 | 07:34am EST

NORTH CHICAGO, Ill. - AbbVie (NYSE: ABBV) announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the efficacy and safety of RINVOQ (upadacitinib; 15 mg, once daily) in patients with active ankylosing spondylitis (AS) who had an inadequate response to biologic DMARD therapy. In this study, RINVOQ met its primary endpoint of Assessment in SpondyloArthritis International Society (ASAS) 40 response and all ranked secondary endpoints at week 14.1 Significantly more RINVOQ-treated patients achieved ASAS40 response at week 14 compared to placebo (45 percent versus 18 percent; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ABBVIE INC.
11/30AbbVie Seeks European Approval for Risankizumab in Moderate to Severe Crohn's Disease
MT
11/30ABBVIE : The Alliance for Endometriosis Survey Reveals Actions Needed to Improve the Endom..
PU
11/30AbbVie Submits Europe Application for Risankizumab for Crohn's Disease
DJ
11/30AbbVie Submits Application for Risankizumab (SKYRIZI«) in Moderate to Severe Crohn's Di..
PR
11/24Truist Adjusts Price Target on AbbVie to $135 From $118, Maintains Buy Rating
MT
11/24NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/23AbbVie Shares Rise After Societe Generale's Upgrade, Price Target Hike
MT
11/23Societe Generale Upgrades AbbVie to Buy from Hold, Raises Price Target to $172 From $11..
MT
11/23WALL STREET STOCK EXCHANGE : The Fed cannot stop Covid
11/23AbbVie to Present at the Evercore ISI Conference
PR
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 248 M - -
Net income 2021 11 451 M - -
Net Debt 2021 63 490 M - -
P/E ratio 2021 17,9x
Yield 2021 4,51%
Capitalization 204 B 204 B -
EV / Sales 2021 4,75x
EV / Sales 2022 4,26x
Nbr of Employees 50 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 115,28 $
Average target price 130,14 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.7.59%203 801
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871